Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE W DEXTROSE 4 25 IN PLASTIC CONTAINER versus DIANEAL 137 W DEXTROSE 4 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIALYTE W DEXTROSE 4 25 IN PLASTIC CONTAINER versus DIANEAL 137 W DEXTROSE 4 25 IN PLASTIC CONTAINER.
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER vs DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intraperitoneal administration of dextrose creates an osmotic gradient that promotes ultrafiltration and removal of uremic toxins and excess fluid across the peritoneal membrane, while electrolytes in the solution correct imbalances.
Intraperitoneal administration of Dianeal with 4.25% dextrose creates an osmotic gradient across the peritoneal membrane, promoting ultrafiltration and removal of uremic toxins and excess fluid.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges per day, via continuous ambulatory peritoneal dialysis (CAPD).
Intraperitoneal administration: 2 liters infused over 10-20 minutes, dwell time 4-6 hours, then drain over 15-20 minutes; 4 exchanges per 24 hours.
None Documented
None Documented
Not applicable (combination product); dextrose follows glucose kinetics (~1.5–2 h); electrolytes have no half-life.
Dextrose: approximately 1.5–2 hours (systemic half-life in renal impairment; peritoneal equilibration half-life for dextrose in dialysate is 1–2 hours, reflecting absorption).
Primarily renal; glucose is reabsorbed or metabolized; electrolytes follow renal handling. Not applicable as a drug; dialysate components are removed via peritoneal dialysis effluent.
Peritoneal dialysis: Dextrose is metabolized systemically and eliminated primarily as CO2. Unchanged dextrose undergoes renal elimination only in anuric patients on dialysis, with minimal biliary/fecal excretion (<2%).
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution